NYSE:OGNPharmaceuticals
Can VTAMA’s New AD Data Offset Earnings Weakness in Shaping Organon’s (OGN) Dermatology Strategy?
Organon recently presented post-hoc pooled Phase 3 ADORING 1 and 2 data on VTAMA cream at the 2026 American Academy of Dermatology meeting, showing early and consistent improvements in atopic dermatitis signs and itch in patients aged 2 and older versus vehicle through eight weeks of treatment.
While VTAMA cream’s dual indication in plaque psoriasis and atopic dermatitis highlights Organon’s push into higher-margin dermatology therapies, recent earnings weakness and negative analyst...